Compare
Arrowhead Pharmaceuticals, Inc. vs Harmony Biosciences Holdings, Inc. vs Collegium Pharmaceutical, Inc vs ANI Pharmaceuticals Inc
| Latest fiscal year | Arrowhead Pharmaceuticals, Inc. ARWR | Harmony Biosciences Holdings, Inc. HRMY | Collegium Pharmaceutical, Inc COLL | ANI Pharmaceuticals Inc ANIP |
|---|---|---|---|---|
| Year ended | 2025-09-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $829.45M | $868.45M | $780.57M | $883.37M |
| Revenue growth (YoY) | n/m | +21.5% | +23.6% | +43.8% |
| Gross margin | n/a | 77.2% | 59.3% | n/a |
| Operating margin | 11.9% | 24.0% | 23.0% | 12.6% |
| Net margin | 3.6% | 18.3% | 8.1% | 8.9% |
| Net income | $30.11M | $158.69M | $62.87M | $78.34M |
| EPS (Diluted) | -$0.01 | $2.71 | $1.73 | $3.32 |
| Operating cash flow | $179.55M | $348.20M | $329.32M | $185.22M |
| Free cash flow | $156.89M | $347.89M | $327.58M | $171.39M |
| Cash & equivalents | n/a | $752.50M | $231.25M | $285.58M |
| Total assets | $1.39B | $1.27B | $1.66B | $1.44B |
| Total liabilities | n/a | $401.41M | $1.36B | $899.65M |
| Shareholders' equity | $503.42M | $870.22M | $301.68M | $540.72M |
| Return on year-end equity | 6.0% | 18.2% | 20.8% | 14.5% |
| Shares outstanding | 135.70M | 57.73M | 31.71M | 22.49M |
Revenue, most recent five fiscal years
| Fiscal year | Arrowhead Pharmaceuticals, Inc. | Harmony Biosciences Holdings, Inc. | Collegium Pharmaceutical, Inc | ANI Pharmaceuticals Inc |
|---|---|---|---|---|
| Latest | $829.45M Ended 2025-09-30 | $868.45M Ended 2025-12-31 | $780.57M Ended 2025-12-31 | $883.37M Ended 2025-12-31 |
| 1 year earlier | $3.55M Ended 2024-09-30 | $714.73M Ended 2024-12-31 | $631.45M Ended 2024-12-31 | $614.38M Ended 2024-12-31 |
| 2 years earlier | $240.74M Ended 2023-09-30 | $582.02M Ended 2023-12-31 | $566.77M Ended 2023-12-31 | $486.82M Ended 2023-12-31 |
| 3 years earlier | $243.23M Ended 2022-09-30 | $437.86M Ended 2022-12-31 | $463.93M Ended 2022-12-31 | $316.38M Ended 2022-12-31 |
| 4 years earlier | $138.29M Ended 2021-09-30 | $305.44M Ended 2021-12-31 | $276.87M Ended 2021-12-31 | $216.14M Ended 2021-12-31 |